Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia. The drug comes with a fascinating history, and in many ways was a ...
Pfizer will have to cut the price of its leukaemia drug Mylotarg to get regular funding from the NHS, after England’s NICE said it could only be used in about 35% of eligible patients.
To date, the US Food and Drug Administration has only approved four anticancer ADCs since Wyeth’s Mylotarg came to market almost 20 years ago. The travails of the ADC sector can be partly ...
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with ...
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with signif ...